EN ESTA TEMPORADA FESTIVA, ST. JUDE CHILDREN’S RESEARCH HOSPITAL TE INVITA A PARTICIPAR EN SU CAMPAÑA THANKS AND GIVING. ® UN PROGRAMA ANUAL QUE BUSCA CREAR CONCIENCIA Y RECAUDAR FONDOS PARA COMBATIR EL CÁNCER INFANTIL.
St. Jude Children’s Research Hospital® officials and guests today marked the opening of the St. Jude Red Frog Events Proton Therapy Center, the first proton therapy center in the world dedicated solely to children with cancer.
Patients are now being treated at the center using precisely delivered, high-energy particles called protons to kill or shrink tumors while minimizing damage to healthy tissue and organs. For patients with brain tumors and certain other cancers, research suggests proton beam therapy may be more effective than conventional radiation at preventing the growth and spread of tumors while reducing the risk of treatment-related side effects.
To view the multimedia release go to:
http://www.multivu.com/players/English/7713451-st-jude-proton-therapy-opening/
To speed progress against cancer and other diseases, the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project today announced the largest-ever release of comprehensive human cancer genome data for free access by the global scientific community. The amount of information released more than doubles the volume of high-coverage, whole genome data currently available from all human genome sources combined. This information is valuable not just to cancer researchers, but also to scientists studying almost any disease.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52993-st-jude-childrens-research-hospital-comprehensive-human-cancer-genome-data
Research led by the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project has identified a fusion gene responsible for almost 30 percent of a rare subtype of childhood leukemia with an extremely poor prognosis.
The finding offers the first evidence of a mistake that gives rise to a significant percentage of acute megakaryoblastic leukemia (AMKL) cases in children. AMKL accounts for about 10 percent of pediatric acute myeloid leukemia (AML). The discovery paves the way for desperately needed treatment advances.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58586-st-jude-children-s-research-hospital-gene-sequencing-childhood-leukemia
NFL PLAY 60, the National Football League’s youth health and fitness campaign, is the new “Official Champion of Play” at St. Jude Children’s Research Hospital®, the global leader in finding cures and saving children with cancer and other deadly diseases.
To commemorate this new milestone in the ongoing partnership between the NFL and St. Jude, a St. Jude patient will join NFL commissioner Roger Goodell on stage to announce a pick during the first round of the 2013 NFL Draft. The NFL Network and ESPN will televise live coverage of the NFL Draft beginning at 8 p.m. EST on Thursday, April 25.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58566-st-jude-children-s-research-hospital-nfl-play-60
Evidence from the Childhood Cancer Survivor Study suggests that changes in childhood cancer treatment have reduced deaths from the late effects of cancer treatment and extended the lives of childhood cancer survivors. St. Jude Children’s Research Hospital investigators led the research, which will be presented today at the plenary session of the 2015 annual meeting of the American Society of Clinical Oncology (ASCO).
The study is one of four being featured at the plenary session press briefing, which highlights research that ASCO deems as having the highest scientific merit and greatest potential to affect patient care.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7532851-st-jude-cancer-research/
Lancôme is unveiling Genes Day on October 22, a one day fundraiser in support of St. Jude Children’s Research Hospital.
In celebration of the beauty of scientific research, Lancôme will donate $7 from each bottle of their latest skin care breakthrough, Génifique Youth Activating Concentrate, sold that day to St. Jude Children’s Research Hospital to support the research and treatment at St. Jude.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/lancome/46646/
Wolfram P. Kastner und Martin Krenn,
Schwere Sachbeschädigung – oder notwendige Ergänzung eines gefälschten Zitats?
Die Republik Österreich, Landesgericht Salzburg, hat gegen den Künstler Wolfram P. Kastner, der zusammen mit Martin Krenn eine Klasse an der Sommerakademie für Bildende Kunst 2001 leitete, ein Strafverfahren wegen „schwerer Sachbeschädigung“ eingeleitet und ein deutsches Amtsgericht um Amtshilfe und „Abhörung“ ersucht.
Was ist der Grund?
Der Begründer des Zionismus, Dr. Theodor Herzl, der sein Rechtsreferendariat am Salzburger Landesgericht ableistete, schrieb in sein Tagebuch: „In Salzburg brachte ich einige der glücklichsten Stunden meines Lebens zu. Ich wäre auch gerne in dieser schönen Stadt geblieben, aber als Jude wäre ich nie zur Stellung eines Richters befördert worden.“
Die Stadt Salzburg brachte im Jahr 2001 dort eine Marmortafel mit dem sinnentstellend verkürzten Zitat an: „In Salzburg brachte ich einige der glücklichsten Stunden meines Lebens zu.“
Am 29. August 2001 nahmen Wolfram P. Kastner und Martin Krenn mit den Studierenden in aller Öffentlichkeit eine handschriftliche Vervollständigung des Zitats vor. Sie sahen darin eine „Rückgabe der unterschlagenen Worte“, in der Hoffnung, daß dies die Verantwortlichen dazu bewegen könnte, ihren Fehler zu erkennen und zu verbessern.
Martin Krenn: „Die Tendenz zur Kriminalisierung von politischen Aktionen und die Einschränkung der künstlerischen Freiheit nimmt in Österreich bedauerlicher Weise zu. Aus meiner Sicht muß dem entschieden entgegen getreten werden.“
New findings from the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project (PCGP) have helped identify the mechanism that makes the childhood eye tumor retinoblastoma so aggressive. The discovery explains why the tumor develops so rapidly while other cancers can take years or even decades to form.
The finding also led investigators to a new treatment target and possible therapy for the rare childhood tumor of the retina, the light-sensing tissue at the back of the eye. The study appears in the January 11 advance online edition of the scientific journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46767-st-jude-genome-project-treatment-childhood-eye-tumor-retinoblastoma
Researchers have discovered that a subtype of leukemia characterized by a poor prognosis is fueled by mutations in pathways distinctly different from a seemingly similar leukemia associated with a much better outcome. The findings from the St. Jude Children’s Research Hospital — Washington University Pediatric Cancer Genome Project (PCGP) highlight a possible new strategy for treating patients with this more aggressive cancer.
The work provides the first details of the genetic alterations fueling a subtype of acute lymphoblastic leukemia (ALL) known as early T-cell precursor ALL (ETP-ALL). The results suggest ETP-ALL has more in common with acute myeloid leukemia (AML) than with other subtypes of ALL. The study appears in the January 12 edition of the journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46768-st-jude-cancer-genome-sequencing-project-combat-aggressive-leukemia
